CompletedNot Applicable

Diagnostic Efficacy of Molecular Diagnostic Method for AMR in ABOiKT

South Korea30 participantsStarted 2020-05-19

Plain-language summary

The purpose of this study is to determine whether the peripheral blood marker-based molecular diagnostic method developed in the previous study can differentiate and predict accommodation and antibody-mediated rejection (AMR) in ABO blood type incompatible kidney transplant (ABOiKT) patients who are prospectively recruited.

Who can participate

Age range19 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * ABO blood group incompatible kidney transplant patients * Patients who consent to written consent * Patients over 19 years of age Exclusion Criteria: * Pregnant patients * Patients with a history of drug abuse within the last 6 months * Psychiatric disease history (major depression, bipolar disorder, schizophrenia, etc.) * Patients who do not want to participate in this study

What they're measuring

The value by logistic regression equation using peripheral blood marker on the 7th day after ABOiKT for prediction of antibody-mediated rejection

Timeframe: the 7th day after ABO-incompatible kidney transplantation

Trial details

NCT IDNCT04541914

SponsorSeoul National University Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2023-12-31

View on ClinicalTrials.gov More ABO Blood Type Incompatible Kidney Transplantation trials